{
    "clinical_study": {
        "@rank": "97597", 
        "arm_group": {
            "arm_group_label": "plitidepsin + bortezomib + dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).\nBortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.\nDexamethasone will be taken orally on D1, 8, 15 and 22, q4wk, for a maximum of eight cycles."
        }, 
        "brief_summary": {
            "textblock": "Study of Plitidepsin (Aplidin\u00ae)  to determine the recommended dose (RD) of plitidepsin in\n      Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory\n      Multiple Myeloma."
        }, 
        "brief_title": "Study of Plitidepsin (Aplidin\u00ae) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of\n      Plitidepsin (Aplidin\u00ae) to determine the recommended dose (RD) of plitidepsin in combination\n      with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple\n      myeloma (MM), to determine the efficacy of the combination\n      plitidepsin/bortezomib/dexamethasone, to evaluate the safety and tolerability of the\n      combination in patients with relapsing and/or refractory MM and to study the\n      pharmacokinetics (PK) and pharmacodynamics (PDy) of plitidepsin in combination with\n      bortezomib and dexamethasone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years.\n\n          -  Prior autologous transplantation (HSCT) patients are allowed.\n\n          -  Patients must have received at least one previous treatment line of induction,\n             chemotherapy, chemotherapy and transplantation or previous treatment with bortezomib\n             or another proteasome drug\n\n        Exclusion Criteria:\n\n          -  Previous treatment with plitidepsin.\n\n          -  Active or metastatic primary malignancy other than MM.\n\n          -  Serious concomitant systemic disorders\n\n          -  History of hypersensitivity reactions to bortezomib, polyoxyl 35 castor oil or\n             mannitol\n\n          -  Neuropathy\n\n          -  Pregnant and/or lactating women\n\n          -  HIV infection\n\n          -  Active hepatitis B or C virus infection.\n\n          -  Treatment with any Investigational Medicinal Product (IMP) in the 30 days before\n             inclusion in the study\n\n          -  Plasma cell leukemia at the time of study entry\n\n          -  Contraindication for the use of steroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100657", 
            "org_study_id": "APL-A-012-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "plitidepsin + bortezomib + dexamethasone", 
                "intervention_name": "Plitidepsin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "plitidepsin + bortezomib + dexamethasone", 
                "intervention_name": "Bortezomib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "plitidepsin + bortezomib + dexamethasone", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bortezomib", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "multiple myeloma", 
            "plitidepsin", 
            "APLIDIN"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Plitidepsin (Aplidin\u00ae) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM).\nTo define the RD, patients will be evaluated for DLTs during the first 28-day cycle. The RD will be the highest DL at which fewer than two out of six (33%) of evaluable patients experience a DLT during the first 28-day cycle.", 
            "measure": "Recommended dose of plitidepsin in combinatio with bortezomib and dexamethasone", 
            "safety_issue": "Yes", 
            "time_frame": "After 28-day cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "PharmaMar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaMar", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}